


CANCER COLLECTION

2024



JCB Journal of
Cell Biology

JEM Journal of
Experimental
Medicine


Life Science Alliance

TOOLS FOR DISCOVERY



Journal of Cell Biology (JCB) publishes advances in any area of basic cell biology as well as applied cellular advances in fields such as cancer biology, immunology, neurobiology, stem cell biology, and metabolism. All editorial decisions on research manuscripts are made through collaborative consultation between professional editors with scientific training and academic editors who are active in the field. JCB was established in 1955.

www.jcb.org



Journal of Experimental Medicine (JEM) publishes papers providing novel conceptual insight into immunology, cancer biology, neuroscience, vascular biology, microbial pathogenesis, and stem cell biology. All editorial decisions are made by active scientists in conjunction with professional editors. JEM was established in 1896.

www.jem.org



Journal of General Physiology (JGP) publishes mechanistic and quantitative cellular and molecular physiology of the highest quality; provides a best in class author experience; and nurtures future generations of researchers. All editorial decisions on research manuscripts are made through a collaborative consultation between the Editor-in-Chief and Associate Editors, all of whom are active scientists. JGP was established in 1918.

www.jgp.org



Life Science Alliance (LSA) is a global, open-access, editorially independent, and peer-reviewed journal launched in 2018 by an alliance of EMBO Press, Rockefeller University Press, and Cold Spring Harbor Laboratory Press. Life Science Alliance is committed to rapid, fair, and transparent publication of valuable research from across all areas in the life sciences.

www.lsajournal.org



LEARN MORE AT RUPRESS.ORG

WHY SUBMIT TO ROCKEFELLER UNIVERSITY PRESS JOURNALS



Format Neutral

You may submit your papers in ANY format.



Transfer Policy

We welcome submissions that include reviewer comments from another journal.



Fair and Fast

Articles appear online one to two days after author proofs are returned.

INSTRUCTIONS FOR AUTHORS

Scan QR code with your phone



Life Science Alliance





CANCER COLLECTION 2024

The editors of the *Journal of Cell Biology* (JCB), *Journal of Experimental Medicine* (JEM), and *Life Science Alliance* (LSA) are pleased to present a special combined collection of recently published articles that elucidate new advances within the field of cancer research. If you enjoy this collection, we encourage you to scan the QR codes below to view the full online collections and sign up for email alerts to receive the latest research.

	A cancer-associated exon alters talin-1 mechanosensitivity and cell motility	7
	Lina M. Gallego-Paez, William J.S. Edwards, Manasa Chanduri ... Jan Mauer and Benjamin Thomas Goult	
	PIM1 kinase drives hypoxia-induced prostate cancer cell invasion	7
	Corbin C. Jensen ... Noel A. Warfel	
	B cell lymphomas may be vulnerable to inhibitors of phosphatidylserine synthesis	8
	Jumpei Omi ... Junken Aoki	
	Melanoma cells enhance their migration by repressing a keratinocyte adhesion molecule	8
	Hope E. Burks ... Kathleen J. Green	
	TGF-β-induced HER2 phosphorylation promotes breast cancer progression	9
	Qiaoni Shi ... Ye-Guang Chen	
	EML4-ALK drives lung adeno-to-squamous transition	10
	Zhen Qin, Meiting Yue, Shijie Tang, Fengying Wu, Honghua Sun ... Xuiliang Zhu, Liang Chen, Shengxiang Ren, Luo-Nan Chen and Hongbin Ji	
	Clonal hematopoiesis promotes colon cancer	10
	Yang Feng ... Olga A. Guryanova	
	E-cadherin loss promotes transcriptional reprogramming and immune evasion in DGAC	11
	Gengyi Zou, Yuanjian Huang ... Jae-Il Park	
	MHC-II⁺ breast cancer cells promote immune tolerance and metastasis	11
	Pin-Ji Lei, Ethel R. Pereira ... Semir Beyaz and Timothy P. Padera	
	Macrophage proliferation drives PDAC progression and immunotherapy susceptibility	12
	Chong Zuo ... David G. DeNardo	
	Targeting chronic lymphocytic leukemia with a splicing factor inhibitor	13
	Irene López-Oreja ... Juan Valcárcel, Sophie Bonnal, and Dolores Colomer	
	Spt5 depletion inhibits Myc-driven tumor growth in flies	13
	Julia Hofstetter, Ayoola Ogunleye, ... Elmar Wolf, Thomas Raabe, and Peter Gallant	
	A Src-NRF2 axis resists radiation-induced ferroptosis in glioblastoma	14
	Claudia Cirotti ... Daniela Barilà	
	The mitochondrial protease OMA1 reduces sarcoma immunogenicity	14
	Richard Miallot ... Philippe Naquet	
	The thiol-reactive compound APR-246 enhances tumor immunogenicity	15
	Judith Michels, Divya Venkatesh ... Jedd D. Wolchok and Taha Merghoub	

Brochure articles by Ben Short, PhD
Design by Yuko Tonohira

On the cover: Image shows the organization of actin in a breast cancer cell under low oxygen conditions.

© 2023 Jensen et al. See
<https://doi.org/10.1083/jcb.202208136>



Editor-In-Chief

Jodi Nunnari

Executive Editor

Tim Spencer

email: tspencer@rockefeller.edu

Editors

Arshad Desai

Pier Paolo Di Fiore

Elaine Fuchs

Anna Huttenlocher

Ian Macara

Ira Mellman

Ana Pombo

Louis F. Reichardt

Kenneth M. Yamada

Richard Youle

Hong Zhang

Senior Scientific Editor, Reviews

Andrea Marat

email: amarat@rockefeller.edu

Scientific Editors

Tim Fessenden

email: tfessenden@rockefeller.edu

Dan Simon

email: dsimon01@rockefeller.edu

Managing Editor

Lindsey Hollander

email: jcellbiol@rockefeller.edu

Editorial Board

John Aitchison

Gregory Alushin

Johan Auwerx

Manuela Baccarini

Tamas Balla

Maureen Barr

Bill Bement

Dominique Bergmann

Anne Bertolotti

Monica Bettencourt-Dias

Joerg Bewersdorf

Magdalena Bezanilla

Cédric Blanpain

Julius Brennecke

Marianne Bronner

Tamara Caspary

Valérie Castellani

Daniela Cimini

Don W. Cleveland

Nika Danial

William Earnshaw

Jan Ellenberg

Anne Ephrussi

Cagla Eroglu

Jeffrey Esko

Sandrine Etienne-Manneville

Andrew Ewald

Marc Freeman

Judith Frydman

Hironori Funabiki

Melissa Gardner

Larry Gerace

Bruce Goode

Yukiko Gotoh

Roger Greenberg

Ulrich Hartl

Martin Hetzer

Tatsuya Hirano

Erika Holzbaur

Martin Humphries

James Hurley

Fumiyo Ikeda

Luisa Iruela-Arispe

Johanna Ivaska

Tarun Kapoor

Gerard Karsenty

Alexey Khodjakov

Hiroshi Kimura

Jürgen Knoblich

Alberto R. Kornblihtt

Ulrike Kutay

Laura Lackner

Thomas Langer

Pekka Lappalainen

Michael Lazarou

Ana Maria Lennon-Dumenil

Andres Leschziner

Danny Lew

Jens Lykke-Andersen

Vivek Malhotra

Brendan Manning

Satyajit Mayor

Tobias Meyer

Liz Miller

Alex Mogilner

Sean Munro

Maxence Nachury

Karla Neugebauer

Carien Niessen

Eva Nogales

Karen Oegema

Kassandra Ori-McKenney

Mark Peifer

Elior Peles

Tatiana Petrova

Gaia Pigino

Will Prinz

Thomas Rando

Samara Reck-Peterson

Michael Rout

Craig Roy

Michael Rudnicki

Erik Sahai

Martin Schwartz

Shu-ou Shan

Andrey Shaw

Zu-Hang Sheng

Agata Smogorzewska

Joan Steitz

Harald Stenmark

Jennifer Stow

Aaron Straight

Lloyd Trotman

Billy Tsai

Elçin Ünal

Bas van Steensel

Patrik Verstreken

Mark von Zastrow

Erwin Wagner

Tobias Walther

Xiaochen Wang

Lois Weisman

Sara Wickström

Min Wu

Hongyuan Yang

Tamotsu Yoshimori

Li Yu

Xiang Yu

Marino Zerial

Yixian Zheng

Bo Zhong

Senior Preflight Editor

Laura Smith

Preflight Editor

Rochelle Ritacco

Assistant Production Editor

Elissa Hunter

Senior Production Editor

Samantha Wolner

Senior Production Manager

Camille Clowery

Production Designer

Erinn A. Grady

Copyright to articles published in this journal is held by the authors. Articles are published by Rockefeller University Press under license from the authors. Conditions for reuse of the articles by third parties are listed at <http://www.rupress.org/terms>.

Print ISSN: 0021-9525.

Online ISSN: 1540-8140

Rockefeller University Press

Executive Editor

Shachi Bhatt

email: jem@rockefeller.edu

Editorial Board Co-Chairs

Carl Nathan

Michel Nussenzweig

Editors

Yasmine Belkaid

Jean-Laurent Casanova

Sara Cherry

Susan Kaech

Jonathan Kipnis

Lewis L. Lanier

Anne O'Garra

Emmanuelle Passegué

Alexander Rudensky

Arlene Sharpe

David Tuveson

Jedd D. Wolchok

Deputy Editors

Xin (Cindy) Sun

Gaia Trincucci

Senior Scientific Editor

Montserrat Cols

Scientific Editors

Lucie Van Emmenis

Zhijuan Qiu

Associate Editors

Elena Hsieh

Caroline Menard

Stefanie Spranger

Franklin Zhong

Editors Emeriti

William A. Muller

Alan Sher

Consulting Biostatistical Editor

Xi Kathy Zhou

Senior Managing Editor

Sylvia F. Cuadrado

phone (212) 327-8575

email: jem@rockefeller.edu

Advisory Editors

Andrea Ablasser

Katerina Akassoglou

Shizuo Akira

Kari Alitalo

Frederick Alt

David Artis

Antonio Bertolotti

Meinrad Busslinger

Arturo Casadevall

Zhijian Chen

Hongbo Chi

Nicholas Chiorazzi

Paul Cohen

Carolyn Coyne

Myron Cybulsky

Vishva Deep Dixit

Greg Delgoffe

Gina DeNicola

Chen Dong

Glenn Dranoff

Michael Dustin

Elaine Dzierzak

Mikala Egeblad

Olivier Elemento

Slava Epelman

Donna Farber

Kate Fitzgerald

Richard Flavell

Thomas Gajewski

Li Gan

Adolfo Garcia-Sastre

Patricia Gearhart

Ronald Germain

Margaret Goodell

Christopher Goodnow

Bertie Gottgens

Florian Greten

Philippe Gros

David Holtzman

Chyi Hsieh

Christopher Hunter

Matteo Iannacone

Luisa Iruela-Arispe

Akiko Iwasaki

Jos Jonkers

Nik Joshi

Johanna Joyce

Yibin Kang

Thirumala-Devi Kanneganti

Gerard Karsenty

Jay Kolls

Paul Kubes

Vijay Kuchroo

Ralf Kuppers

Tomohiro Kurosaki

Bart Lambrecht

Jongsoon Lee

Ross Levine

Klaus Ley

Clare Lloyd

Burkhard Ludewig

Lydia Lynch

John Macmicking

Tak Mak

Asrar Malik

Bernard Malissen

Nicolas Manel

Philippa Marrack

Diane Mathis

Ira Mellman

Miriam Merad

Matthias Merkenschlager

Hanna Mikkola

Denise Monack

Daniel Mucida

Cornelis Murre

John O'Shea

Oliver Pabst

Jack Parent

Virginia Pascual

Laura Pasqualucci

Erika L. Pearce

Fiona Powrie

Klaus Rajewsky

Gwendalyn Randolph

Rino Rappuoli

Jeffrey Ravetch

Kodi Ravichandran

Nicholas Restifo

Jeremy Rich

Ellen Rothenberg

Carla Rothlin

Shimon Sakaguchi

Vijay Sankaran

Matthew Scharff

Hans Schreiber

Pamela Schwartzberg

Charles Serhan

Mara Sherman

Ethan Shevach

Robert Siliciano

Roy Silverstein

Jo Spencer

Hergen Spits

Jonathan Sprent

Ulrich Steidl

Andreas Strasser

Helen Su

Joseph Sun

Filip Swirski

Elia Tait Wojno

Stuart Tangye

Steven Teitelbaum

Jenny Ting

Victor Torres

Kevin Tracey

Giorgio Trinchieri

Li-Huei Tsai

Shannon Turley

Valerie Weaver

E. John Wherry

Thomas Wynn

Sayuri Yamazaki

Zeming Zhang

Leonard Zon

Weiping Zou

Monitoring Editors

Marco Colonna

Jason Cyster

Stephen Hedrick

Kristin Hogquist

Andrew McMichael

Luigi Notarangelo

Federica Sallusto

Toshio Suda

Senior Preflight Editor

Laura Smith

Preflight Editor

Rochelle Ritacco

Assistant Production Editor

Elissa Hunter

Production Editor

Jennifer McCullam

Senior Production Manager

Camille Clowery

Production Designer

Erinn A. Grady

Copyright to articles published in this journal is held by the authors. Articles are published by Rockefeller University Press under license from the authors. Conditions for reuse of the articles by third parties are listed at <http://www.rupress.org/terms>

Print ISSN 0022-1007

Online ISSN 1540-9538

Rockefeller University Press



Life Science Alliance

Executive Editor

Eric Sawey

e.sawey@life-science-alliance.org

Scientific Editor

Novella Guidi

n.guidi@life-science-alliance.org

Academic Editors

Julia Cooper

Florent Ginhoux

Sebastian Jessberger

Michael Overholtzer

Judith Zaugg

Editorial Assistant

Reilly Lorenz

r.lorenz@life-science-alliance.org

tel: +49 6221 8891 414

Editorial Advisory Board

Asifa Akhtar

Madan Babu

Erika Bach

Eric Baehrecke

Marek Basler

Tuncay Baubec

Pedro Beltrao

Kerry Bloom

Shiqing Cai

Rafael Carazo-Salas

Monica Carson

Andrew Carter

Wei Chen

Xuemei Chen

Jerry Chipuk

Orna Cohen-Fix

Lélia Delamarre

Vlad Denic

Scott Dixon

Anne Eichmann

Barbara Engelhardt

Nicolas Fazilleau

Sarah-Maria Fendt

Yasuyuki Fujita

Eileen Furlong

Ian Ganley

Ana J. García-Sáez

Sonia Garel

Mary Gehring

Saghi Ghaffari

Jesús Gil

Michael Glotzer

Miguel Godinho Ferreira

Todd Golde

Yukiko Gotoh

Thomas Gregor

Melanie Greter

Howard Hang

Silke Hauf

Cole Haynes

Myriam Heiman

Simon Hippenmeyer

Tatsushi Igaki

Jacqueline Jacobs

Carsten Janke

Cigall Kadoch

Shingo Kajimura

Raghu Kalluri

Gary Karpen

Réne Ketting

Claudine Kraft

Ulrike Kutay

Tuuli Lappalainen

Eros Lazzerini-Denchi

François Leulier

Guanghui Liu

Mofang Liu

Emma Lundberg

Laura Machesky

Kay Macleod

Shyamala Maheswaran

Taija Makinen

Susan Mango

Jean-Christophe Marine

Sophie Martin

Kyle Miller

Maria M. Mota

Christian Münz

Andrew J. Murphy

Dimple Notani

Søren Paludan

Staffan Persson

Dana Philpott

Katherine Pollard

Jody Rosenblatt

Carla Rothlin

Aurélien Roux

Jared Rutter

Marco Sandri

Maya Schuldiner

Carmine Settembre

Agnel Sfeir

John Silke

David L. Silver

Lori Sussel

Stephen Tait

Shubha Tole

Iva Tolić

Athanasios Typas

Igor Ulitsky

Jan-Willem Veening

Thierry Walzer

Shizhen (Emily) Wang

Yibin Wang

Hedda Wardemann

Dolf Weijers

Kathryn Wellen

James Wells

Eske Willerslev

R. Luke Wiseman

Will Wood

Julia Zeitlinger

Yi Ariel Zeng

Xiang (Shawn) Zhang

A CANCER-ASSOCIATED EXON ALTERS TALIN-1 MECHANOSENSITIVITY AND CELL MOTILITY

Talin-1 is the core mechanosensitive adapter protein linking integrins to the cytoskeleton. The *TLN1* gene is comprised of 57 exons that encode the 2,541 amino acid TLN1 protein. TLN1 was previously considered to be expressed as a single isoform. However, through differential pre-mRNA splicing analysis, we discovered a cancer-enriched, non-annotated 51-nucleotide exon in *TLN1* between exons 17 and 18, which we refer to as exon 17b.

TLN1 is comprised of an N-terminal FERM domain, linked to 13 force-dependent switch domains, R1-R13. Inclusion of exon 17b introduces an in-frame

insertion of 17 amino acids immediately after Gln665 in the region between R1 and R2, which lowers the force required to open the R1-R2 switches potentially altering downstream mechanotransduction.

Biochemical analysis of this isoform revealed enhanced vinculin binding, and cells expressing this variant show altered adhesion dynamics and motility. Finally, we showed that the TGF- β /SMAD3 signaling pathway regulates this isoform switch. Future studies will need to consider the balance of these two TLN1 isoforms.

ORIGINAL PAPER

Gallego-Paez, L.M., W.J.S. Edwards, M. Chanduri, Y. Guo, T. Koorman, C.-Y. Lee, N. Grexa, P. Derksen, J. Yan, M.A. Schwartz, J. Mauer, and B.T. Goult. 2023. *TLN1* contains a cancer-associated cassette exon that alters talin-1 mechanosensitivity. *J. Cell Biol.* 222 (5): e202209010. <https://doi.org/10.1083/jcb.202209010>

RESEARCHER DETAILS



Lina M. Gallego-Paez
Postdoctoral Research Scientist
BioMed X Institute (GmbH), Heidelberg



William J.S. Edwards
PhD student
University of Kent



Manasa Chanduri
Postdoctoral Associate
Yale School of Medicine



Jan Mauer
Senior Principal Scientist
Novartis Institutes for BioMedical Research
jan.mauer@novartis.com



Benjamin Thomas Goult
Professor
University of Liverpool
b.t.goult@liverpool.ac.uk



Scan to read the
full article ►

PIM1 KINASE DRIVES HYPOXIA-INDUCED PROSTATE CANCER CELL INVASION

Distinguishing key factors that drive the switch from indolent to invasive disease will make a significant impact on guiding the treatment of prostate cancer (PCa) patients. We identified a novel signaling pathway linking hypoxia and PIM1 kinase to the actin cytoskeleton and cell motility.

An unbiased proteomic screen identified Abl-interactor 2 (ABI2), an integral member of the wave regulatory complex (WRC), as a PIM1 substrate. Phosphorylation of ABI2 at Ser183 by PIM1 increased ABI2 protein levels and enhanced WRC formation, resulting in increased protrusive activity and cell

motility. Cell protrusion induced by hypoxia and/or PIM1 was dependent on ABI2.

In vivo smooth muscle invasion assays showed that overexpression of PIM1 significantly increased the depth of tumor cell invasion, and treatment with PIM inhibitors significantly reduced intramuscular PCa invasion. This research uncovers a HIF-1-independent signaling axis that is critical for hypoxia-induced invasion and establishes a novel role for PIM1 as a key regulator of the actin cytoskeleton.

ORIGINAL PAPER

Jensen, C.C., A.N. Clements, H. Liou, L.E. Ball, J.R. Bethard, P.R. Langlais, R.K. Toth, S.S. Chauhan, A.L. Casillas, S.R. Daulat, A.S. Kraft, A.E. Cress, C.K. Miranti, G. Mouneimne, G.C. Rogers, and N.A. Warfel. 2023. PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion. *J. Cell Biol.* 222 (6): e202208136. <https://doi.org/10.1083/jcb.202208136>

RESEARCHER DETAILS



Corbin C. Jensen
Postdoctoral Fellow
University of North Carolina



Noel A. Warfel
Associate Professor
University of Arizona Cancer Center
warfelna@arizona.edu



Scan to read the
full article ►

B CELL LYMPHOMAS MAY BE VULNERABLE TO INHIBITORS OF PHOSPHATIDYLSERINE SYNTHESIS

Cancer cells harness lipid metabolism to promote their own survival. We screened 47 cancer cell lines for survival dependency on phosphatidylserine (PS) synthesis using a PS synthase 1 (PTDSS1) inhibitor and found that B cell lymphoma is highly dependent on PS.

Inhibition of PTDSS1 in B cell lymphoma cells caused a reduction of PS and phosphatidylethanolamine levels and an increase of phosphoinositide levels. The resulting imbalance of the membrane phospholipidome lowered the activation threshold for B cell receptor (BCR), a B cell-specific survival mechanism. BCR hyperactivation led to

aberrant elevation of downstream Ca^{2+} signaling and subsequent apoptotic cell death. In a mouse xenograft model, PTDSS1 inhibition efficiently suppressed tumor growth and prolonged survival.

Our findings suggest that PS synthesis may be a critical vulnerability of malignant B cell lymphomas that can be targeted pharmacologically.

ORIGINAL PAPER

Omi, J., T. Kato, Y. Yoshihama, K. Sawada, N. Kono, and J. Aoki. 2024. Phosphatidylserine synthesis controls oncogenic B cell receptor signaling in B cell lymphoma. *J. Cell Biol.* 223 (2): e202212074. <https://doi.org/10.1083/jcb.202212074>

RESEARCHER DETAILS



Jumpei Omi
Research Fellow
The University of Tokyo
jomi@mol.f.u-tokyo.ac.jp



Junken Aoki
Professor
The University of Tokyo
jaoki@mol.f.u-tokyo.ac.jp



Scan to read the full article ►

MELANOMA CELLS ENHANCE THEIR MIGRATION BY REPRESSING A KERATINOCYTE ADHESION MOLECULE

Melanoma is an aggressive cancer typically arising from transformation of melanocytes residing in the basal layer of the epidermis, where they are in direct contact with surrounding keratinocytes. The role of keratinocytes in shaping the melanoma tumor microenvironment remains understudied.

We previously showed that temporary loss of the keratinocyte-specific cadherin, Desmoglein 1 (Dsg1), controls paracrine signaling between normal melanocytes and keratinocytes to stimulate the protective tanning response. Here, we provide evidence that melanoma cells hijack this intercellular communication by secreting factors that keep Dsg1 expression low in the

surrounding keratinocytes, which in turn generate their own paracrine signals that enhance melanoma spread through CXCL1/CXCR2 signaling. Evidence suggests a model whereby paracrine signaling from melanoma cells increases levels of the transcriptional repressor Slug, and consequently decreases expression of the Dsg1 transcriptional activator Grhl1.

Together, these data support the idea that paracrine crosstalk between melanoma cells and keratinocytes resulting in chronic keratinocyte Dsg1 reduction contributes to melanoma cell movement associated with tumor progression.

ORIGINAL PAPER

Burks, H.E., J.L. Pokorny, J.L. Koetsier, Q.R. Roth-Carter, C.R. Arnette, P. Gerami, J.T. Seykora, J.L. Johnson, Z. Ren, and K.J. Green. Melanoma cells repress Desmoglein 1 in keratinocytes to promote tumor cell migration. 2023. *J. Cell Biol.* 222 (11): e202212031. <https://doi.org/10.1083/jcb.202212031>

RESEARCHER DETAILS



Hope E. Burks, PhD
Fellow
Chan Zuckerberg Biohub Chicago



Kathleen J. Green, PhD
Joseph L. Mayberry Professor
Feinberg School of Medicine
Northwestern University
kgreen@northwestern.edu



Scan to read the full article ►

TGF- β -INDUCED HER2 PHOSPHORYLATION PROMOTES BREAST CANCER PROGRESSION


Transforming growth factor β (TGF- β) and HER2 signaling collaborate to promote breast cancer progression. However, their molecular interplay is largely unclear. TGF- β can activate mitogen-activated protein kinase (MAPK) and AKT, but the underlying mechanism is not fully understood.

In this study, we report that TGF- β enhances HER2 activation, leading to the activation of MAPK and AKT. This process depends on the TGF- β type I receptor T β RI kinase activity. T β RI phosphorylates HER2 at Ser779, promoting Y1248 phosphorylation and HER2 activation. Mice with HER2 S779A mutation display impaired

mammary morphogenesis, reduced ductal elongation, and branching. Furthermore, wild-type HER2, but not S779A mutant, promotes TGF- β -induced epithelial-mesenchymal transition, cell migration, and lung metastasis of breast cells. Increased HER2 S779 phosphorylation is observed in human breast cancers and positively correlated with the activation of HER2, MAPK, and AKT.

Our findings demonstrate the crucial role of TGF- β -induced S779 phosphorylation in HER2 activation, mammary gland development, and the pro-oncogenic function of TGF- β in breast cancer progression.

RESEARCHER DETAILS



Qiaoni Shi
Postdoctoral Fellow
Tsinghua University



Ye-Guang Chen
Professor
Tsinghua University
ygchen@tsinghua.edu.cn



Scan to read
the full article

ORIGINAL PAPER

Shi, Q., F. Huang, Y. Wang, H. Liu, H. Deng, Y.-G. Chen. 2024. HER2 phosphorylation induced by TGF- β promotes mammary morphogenesis and breast cancer progression. *J. Cell Biol.* 223 (4): e202307138.
<https://doi.org/10.1083/jcb.202307138>

Read the full collection online:

**CANCER
CELL BIOLOGY 2024**



Journal of Cell Biology (JCB) publishes advances in any area of basic cell biology as well as applied cellular advances in fields such as neurobiology, cancer biology, immunology, stem cell biology, and metabolism. All editorial decisions on research manuscripts are made through collaborative consultation between professional editors with scientific training and academic editors who are active in the field. *JCB* was established in 1955.

CONNECT WITH JCB





-  @JCellBiol
-  @JCellBiol
-  @rockefeller_university_press
-  jcb@rockefeller.edu



Image: © 2023 Jensen et al.

JCB.ORG

EML4-ALK DRIVES LUNG ADENO-TO-SQUAMOUS TRANSITION

Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is detectable in 5.1–7.5% of human LUAS, and transgenic expression of EML4-ALK drives lung adenocarcinoma (LUAD) formation initially and squamous transition at late stage.

We identify club cells as the main cell of origin for squamous transition. By recapitulating lineage transition in an organoid system, we identify that JAK-STAT signaling, activated by EML4-ALK phase separation, significantly promotes squamous transition. Integrative study with scRNA-seq and immu-

nostaining identify a plastic cell subpopulation in ALK-rearranged human LUAD showing squamous biomarker expression. Moreover, those relapsed ALK-rearranged LUAD show notable upregulation of squamous biomarkers. Consistently, mouse squamous tumors or LUAD with squamous signature display certain resistance to ALK inhibitor, which can be overcome by combined JAK1/2 inhibitor treatment.

This study uncovers strong plasticity of ALK-rearranged tumors in orchestrating phenotypic transition and drug resistance and proposes a potentially effective therapeutic strategy.

ORIGINAL PAPER

Qin, Z., M. Yue, S. Tang, F. Wu, H. Sun, Y. Li, Y. Zhang, H. Izumi, H. Huang, W. Wang, Y. Xue, X. Tong, S. Mori, T. Taki, K. Goto, Y. Jin, F. Li, F.-M. Li, Y. Gao, Z. Fang, Y. Fang, L. Hu, X. Yan, G. Xu, H. Chen, S.S. Kobayashi, A. Ventura, K.-K. Wong, X. Zhu, L. Chen, S. Ren, L.-N. Chen, and H. Ji. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. 2024. *J. Exp. Med.* 221 (3): e20232028. <https://doi.org/10.1084/jem.20232028>

RESEARCHER DETAILS

Zhen Qin

CAS Center for Excellence in Molecular Cell Science
Shanghai Institute of Biochemistry and Cell Biology
Chinese Academy of Sciences

Meiting Yue

CAS Center for Excellence in Molecular Cell Science
Shanghai Institute of Biochemistry and Cell Biology
Chinese Academy of Sciences

Shijie Tang

CAS Center for Excellence in Molecular Cell Science
Shanghai Institute of Biochemistry and Cell Biology
Chinese Academy of Sciences

Fengying Wu

Tongji University School of Medicine

Honghua Sun

CAS Center for Excellence in Molecular Cell Science
Shanghai Institute of Biochemistry and Cell Biology
Chinese Academy of Sciences

Xueliang Zhu

Professor, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology
Chinese Academy of Sciences
xlzhu@sibcb.ac.cn

Liang Chen

Professor, Jinan University chenliang@jnu.edu.cn

Shengxiang Ren

Professor, Tongji University School of Medicine
harry_ren@126.com

Luo-Nan Chen

Professor, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology
Chinese Academy of Sciences
lnchen@sibs.ac.cn



Hongbin Ji

Professor, CAS Center for Excellence in Molecular Cell Science,

Shanghai Institute of Biochemistry and Cell Biology
Chinese Academy of Sciences
hbji@sibcb.ac.cn

Scan to read
the full article



CLONAL HEMATOPOIESIS PROMOTES COLON CANCER

Clonal hematopoiesis (CH) is defined as clonal expansion of mutant hematopoietic stem cells absent diagnosis of a hematologic malignancy. Presence of CH in solid tumor patients, including colon cancer, correlates with shorter survival. We hypothesized that bone marrow-derived cells with heterozygous loss-of-function mutations of *DNMT3A*, the most common genetic alteration in CH, contribute to the pathogenesis of colon cancer.

In a mouse model that combines colitis-associated colon cancer (CAC) with experimental CH driven by *Dnmt3a*^{+/Δ}, we found higher tumor penetrance and increased tumor burden compared with controls. Histopathological

analysis revealed accentuated colonic epithelium injury, dysplasia, and adenocarcinoma formation. Transcriptome profiling of colon tumors identified enrichment of gene signatures associated with carcinogenesis, including angiogenesis. Treatment with the angiogenesis inhibitor axitinib eliminated the colon tumor-promoting effect of experimental CH driven by *Dnmt3a* haploinsufficiency and rebalanced hematopoiesis.

This study provides conceptually novel insights into non-tumor-cell-autonomous effects of hematopoietic alterations on colon carcinogenesis and identifies potential therapeutic strategies.

ORIGINAL PAPER

Feng, Y., Q. Yuan, R.C. Newsome, T. Robinson, R.L. Bowman, A.N. Zuniga, K.N. Hall, C.M. Bernstein, D.E. Shabashvili, K.I. Krajcik, C. Gunaratne, Z.J. Zaroogian, K. Venugopal, H.L. Casellas Roman, R.L. Levine, W.K. Chatila, R. Yaeger, A. Riva, C. Jobin, D. Kopinke, D. Avram, and O.A. Guryanova. 2023. Hematopoietic-specific heterozygous loss of *Dnmt3a* exacerbates colitis-associated colon cancer. *J. Exp. Med.* 220 (11): e20230011. <https://doi.org/10.1084/jem.20230011>

RESEARCHER DETAILS



Yang Feng

PhD student
University of Florida College of Medicine



Olga A. Guryanova

Associate Professor
University of Florida College of Medicine
oguryanova@ufl.edu

Scan to read the
full article ►



E-CADHERIN LOSS PROMOTES TRANSCRIPTIONAL REPROGRAMMING AND IMMUNE EVASION IN DGAC

Diffuse-type gastric adenocarcinoma (DGAC) is a deadly cancer often diagnosed late and resistant to treatment. While hereditary DGAC is linked to *CDH1* mutations, the role of CDH1/E-cadherin inactivation in sporadic DGAC tumorigenesis remains elusive.

We discovered CDH1 inactivation in a subset of DGAC patient tumors. Analyzing single-cell transcriptomes in malignant ascites, we identified two DGAC subtypes: DGAC1 (CDH1 loss) and DGAC2 (lacking immune response). DGAC1 displayed distinct molecular signatures, activated DGAC-re-

lated pathways, and an abundance of exhausted T cells in ascites. Genetically engineered murine gastric organoids showed that *Cdh1* knock-out (KO), *KrasG12D*, *Trp53* KO (EKP) accelerates tumorigenesis with immune evasion compared with *KrasG12D*, *Trp53* KO (KP). We also identified EZH2 as a key mediator promoting CDH1 loss-associated DGAC tumorigenesis.

These findings highlight DGAC's molecular diversity and potential for personalized treatment in CDH1-inactivated patients.

RESEARCHER DETAILS



Gengyi Zou
Postdoctoral fellow
The University of Texas MD Anderson Cancer Center



Yuanjian Huang
Attending Doctor & Lecturer
The First Affiliated Hospital of Nanjing Medical University



Jae-Il Park
Professor
The University of Texas MD Anderson Cancer Center
jaeil@mdanderson.org



Scan to read the
full article ►

ORIGINAL PAPER

Zou, G., Y. Huang, S. Zhang, K.-P. Ko, B. Kim, J. Zhang, V. Venkatesan, M.P. Pizzi, Y. Fan, S. Jun, N. Niu, H. Wang, S. Song, J.A. Ajani, and J.-I. Park. 2024. E-cadherin loss drives diffuse-type gastric tumorigenesis via EZH2-mediated reprogramming. *J. Exp. Med.* 221 (4): e20230561. <https://doi.org/10.1084/jem.20230561>

MHC-II⁺ BREAST CANCER CELLS PROMOTE IMMUNE TOLERANCE AND METASTASIS

Tumor-draining lymph nodes (TDLNs) are important for tumor antigen-specific T cell generation and effective anticancer immune responses. However, TDLNs are often the primary site of metastasis, causing immune suppression and worse outcomes. Through cross-species single-cell RNA-Seq analysis, we identified features defining cancer cell heterogeneity, plasticity, and immune evasion during breast cancer progression and lymph node metastasis (LNM).

A subset of cancer cells in the lymph nodes exhibited elevated MHC class II

(MHC-II) gene expression in both mice and humans. MHC-II⁺ cancer cells lacked costimulatory molecule expression, leading to regulatory T cell (Treg) expansion and fewer CD4⁺ effector T cells in TDLNs. Genetic knockout of MHC-II reduced LNM and Treg expansion, while overexpression of the MHC-II transactivator, *Ciita*, worsened LNM and caused excessive Treg expansion.

These findings demonstrate that cancer cell MHC-II expression promotes metastasis and immune evasion in TDLNs.

RESEARCHER DETAILS



Pin-Ji Lei
Postdoctoral fellow
Massachusetts General Hospital, Harvard Medical School



Ethel R. Pereira
Postdoctoral fellow
Massachusetts General Hospital, Harvard Medical School
(Now at Bristol Myers Squibb)



Semir Beyaz
Assistant Professor
Cold Spring Harbor Laboratory
beyaz@cshl.edu



Timothy P. Padera
Associate Professor
Massachusetts General Hospital, Harvard Medical School
tpadera@stele.mgh.harvard.edu



Scan to read the
full article ►

ORIGINAL PAPER

Lei, P.J., E.R. Pereira, P. Andersson, Z. Amoozgar, J.W. Van Wijnbergen, M.J. O'Melia, H. Zhou, S. Chatterjee, W.W. Ho, J.M. Posada, A.S. Kumar, S. Morita, L. Menzel, C. Chung, I. Ergin, D. Jones, P. Huang, S. Beyaz, and T.P. Padera. 2023. Cancer cell plasticity and MHC-II-mediated immune tolerance promote breast cancer metastasis to lymph nodes. *J. Exp. Med.* 220 (9): e20221847. <https://doi.org/10.1084/jem.20221847>

MACROPHAGE PROLIFERATION DRIVES PDAC PROGRESSION AND IMMUNOTHERAPY SUSCEPTIBILITY

Tumor-associated macrophages (TAMs) are abundant in pancreatic ductal adenocarcinomas (PDACs). While TAMs are known to proliferate in cancer tissues, the impact of this on macrophage phenotype and disease progression is poorly understood.

We showed that in PDAC, proliferation of TAMs could be driven by colony stimulating factor-1 (CSF1) produced by cancer-associated fibroblasts. CSF1 induced high levels of p21 in macrophages, which regulated both TAM proliferation and phenotype. TAMs in human and mouse PDACs with high levels of p21 had more inflammatory and immunosuppressive phenotypes.

p21 expression in TAMs was induced by both stromal interaction and/or chemotherapy treatment. Finally, by modeling p21 expression levels in TAMs, we found that p21-driven macrophage immunosuppression in vivo drove tumor progression. Serendipitously, the same p21-driven pathways that drive tumor progression also drove response to CD40 agonist.

These data suggest that stromal or therapy-induced regulation of cell cycle machinery can regulate both macrophage-mediated immune suppression and susceptibility to innate immunotherapy.

RESEARCHER DETAILS



Chong Zuo
Graduate student
Washington University School of
Medicine in St. Louis



David G. DeNardo
Professor
Washington University School of
Medicine in St. Louis
ddenardo@wustl.edu

ORIGINAL PAPER

Zuo, C., J.M. Baer, B.L. Knolhoff, J.I. Belle, X. Liu, A.A. De La Lastra, C. Fu, G.D. Hogg, N.L. Kingston, M.A. Breden, P.B. Dodhiawala, D.C. Zhou, V.E. Lander, C.A. James, L. Ding, K.-H. Lim, R.C. Fields, W.G. Hawkins, J.D. Weber, G. Zhao, and D.G. DeNardo. 2023. Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility to innate immunotherapy. *J. Exp. Med.* 220 (6): e20212062. <https://doi.org/10.1084/jem.20212062>



Scan to read the
full article ►

Read the full collection online:

CANCER COLLECTION 2024

SCAN



Journal of Experimental Medicine (JEM) publishes papers providing novel conceptual insight into neuroscience, immunology, cancer biology, vascular biology, microbial pathogenesis, and stem cell biology. All editorial decisions are made by active scientists in conjunction with professional editors. JEM was established in 1896.

CONNECT WITH JEM

@JExpMed

@JExpMed

@rockefeller_university_press

jem@rockefeller.edu

TARGETING CHRONIC LYMPHOCYTIC LEUKEMIA WITH A SPLICING FACTOR INHIBITOR

Splicing factor 3B subunit 1 (SF3B1) is involved in pre-mRNA branch site recognition and is the target of antitumor-splicing inhibitors. Mutations in *SF3B1* are observed in 15% of patients with chronic lymphocytic leukemia (CLL) and are associated with poor prognosis, but their pathogenic mechanisms remain poorly understood.

Using deep RNA-sequencing data from 298 CLL tumor samples and isogenic *SF3B1* WT and K700E-mutated CLL cell lines, we characterize targets and pre-mRNA sequence features associated with the selection of cryptic 3' splice sites upon *SF3B1* mutation, including an event in the

MAP3K7 gene relevant for activation of NF- κ B signaling.

Using the H3B-8800 splicing modulator, we show, for the first time in CLL, cytotoxic effects in vitro in primary CLL samples and in *SF3B1*-mutated isogenic CLL cell lines, accompanied by major splicing changes and delayed leukemic infiltration in a CLL xenotransplant mouse model. H3B-8800 displayed preferential lethality towards *SF3B1*-mutated cells and synergism with the BCL2 inhibitor venetoclax, supporting the potential use of SF3B1 inhibitors as a novel therapeutic strategy in CLL.

ORIGINAL PAPER

López-Oreja, I., A. Gohr, H. Playa-Albinyana, A. Giró, F. Arenas, M. Higashi, R. Tripathi, M. López-Guerra, M. Irimia, M. Aymerich, J. Valcárcel, S. Bonnal, and D. Colomer. 2023. *SF3B1* mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia. *Life Science Alliance*. 6 (11): e202301955. <https://doi.org/10.26508/lsa.202301955>

RESEARCHER DETAILS



Irene López-Oreja

Pre-doctoral researcher
Centre for Genomic Regulation
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Hospital Clínic de Barcelona



Juan Valcárcel

Group Leader
Centre for Genomic Regulation
juan.valcarcel@crg.eu



Sophie Bonnal

Staff Scientist
Centre for Genomic Regulation
sophie.bonnal@crg.eu



Dolores Colomer

Group Leader
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Universitat Barcelona
dcolomer@clinic.cat



Scan to read the full article ►

SPT5 DEPLETION INHIBITS MYC-DRIVEN TUMOR GROWTH IN FLIES

The transcription factor SPT5 physically interacts with MYC oncoproteins and is essential for efficient transcriptional activation of MYC targets in cultured cells. We used *Drosophila* to address the relevance of this interaction in a living organism.

Spt5 displays moderate synergy with Myc in fast proliferating young imaginal disc cells. During later development, Spt5-knockdown has no detectable consequences on its own, but strongly enhances eye defects caused by Myc overexpression. Similarly, Spt5-knockdown in larval type 2 neuroblasts has only mild effects

on brain development and survival of control flies, but dramatically shrinks the volumes of experimentally induced neuroblast tumors and significantly extends the lifespan of tumor-bearing animals.

This beneficial effect is still observed when Spt5 is knocked down systemically and after tumor initiation, highlighting SPT5 as a potential drug target in human oncology.

ORIGINAL PAPER

Hofstetter, J., A. Ogunleye, A. Kutschke, L.M. Buchholz, E. Wolf, T. Raabe, and P. Gallant. 2023. Spt5 interacts genetically with Myc and is limiting for brain tumor growth in *Drosophila*. *Life Science Alliance*. 7 (1): e202302130. <https://doi.org/10.26508/lsa.202302130>

RESEARCHER DETAILS



Julia Hofstetter (left)

Postdoc
University of Würzburg

Peter Gallant (center)

Professor
University of Würzburg
peter.gallant@uni-wuerzburg.de


Thomas Raabe (right)

Professor
University of Würzburg
thomas.raabe@uni-wuerzburg.de



Ayoola Ogunleye

Masters student
University of Würzburg
(Now a PhD student at University of Nebraska Medical Center)



Elmar Wolf

Professor, University of Würzburg
(Now at Kiel University)
elmar.wolf@biochem.uni-kiel.de



Scan to read the full article ►

A SRC-NRF2 AXIS RESISTS RADIATION-INDUCED FERROPTOSIS IN GLIOBLASTOMA

Glioblastoma is a severe brain tumor characterized by an extremely poor survival rate of patients. Glioblastoma cancer cells escape to standard therapeutic protocols consisting of a combination of ionizing radiation and temozolomide alkylating drugs that trigger DNA damage by rewiring of signaling pathways. In recent years, the up-regulation of factors that counteract ferroptosis has been highlighted as a major driver of cancer resistance to ionizing radiation, although the molecular connection between the activation of oncogenic signaling and the modulation of ferroptosis has not been clarified yet.

We provide the first evidence for a molecular connection between the constitutive activation of tyrosine kinases and resistance to ferroptosis. Src tyrosine kinase, a central hub on which deregulated receptor tyrosine kinase signaling converge in cancer, leads to the stabilization and activation of NRF2 pathway, thus promoting resistance to ionizing radiation-induced ferroptosis.

These data suggest that the up-regulation of the Src-NRF2 axis may represent a vulnerability for combined strategies that, by targeting ferroptosis resistance, enhance radiation sensitivity in glioblastoma.

ORIGINAL PAPER

Cirotti, C., I. Taddei, C. Contadini, C. Di Girolamo, G. Pepe, M. De Bardi, G. Borsellino, M. Helmer-Citterich, and D. Barilà. 2023. NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma. *Life Science Alliance*. 7 (1): e202302205. <https://doi.org/10.26508/lsa.202302205>

RESEARCHER DETAILS



Daniela Barilà (left)

Full professor
University of Rome "Tor Vergata"
IRCCS-Fondazione Santa Lucia
daniela.barila@uniroma2.it

Claudia Cirotti (right)

Postdoctoral researcher
University of Rome "Tor Vergata"
IRCCS-Fondazione Santa Lucia
claudiacirotti89@gmail.com

Scan to read the full article ►



THE MITOCHONDRIAL PROTEASE OMA1 REDUCES SARCOMA IMMUNOGENICITY

Aggressive tumors often display mitochondrial dysfunction. Upon oxidative stress, mitochondria undergo fission through OMA1-mediated cleavage of the fusion effector OPA1. In yeast, a redox-sensing switch participates in OMA1 activation. 3D modeling of OMA1 comforted the notion that cysteine 403 might participate in a similar sensor in mammalian cells.

Using prime editing, we developed a mouse sarcoma cell line in which OMA1 cysteine 403 was mutated to alanine. Mutant cells showed impaired mitochondrial responses to stress including ATP production, reduced fission, resistance to apoptosis, and enhanced mitochondrial DNA release. This mutation prevented tumor devel-

opment in immunocompetent, but not nude or cDC1 dendritic cell-deficient, mice. These cells prime CD8⁺ lymphocytes that accumulate in mutant tumors, whereas their depletion delays tumor control. Thus, OMA1 inactivation increased the development of anti-tumor immunity.

Patients with complex genomic soft tissue sarcoma showed variations in the level of OMA1 and OPA1 transcripts. High expression of OPA1 in primary tumors was associated with shorter metastasis-free survival after surgery, and low expression of OPA1, with anti-tumor immune signatures. Targeting OMA1 activity may enhance sarcoma immunogenicity.

ORIGINAL PAPER

Miallot, R., V. Millet, Y. Groult, A. Modelska, L. Crescence, S. Roulland, S. Henri, B. Malissen, N. Brouilly, L. Panicot-Dubois, R. Vincentelli, G. Sulzenbacher, P. Finetti, A. Dutour, J.-Y. Blay, F. Bertucci, F. Galland, and P. Naquet. 2023. An OMA1 redox site controls mitochondrial homeostasis, sarcoma growth, and immunogenicity. *Life Science Alliance*. 6 (6): e202201767. <https://doi.org/10.26508/lsa.202201767>

RESEARCHER DETAILS



Richard Miallot (left)

PhD student
Aix-Marseille Université, Centre d'Immunologie de Marseille-Luminy
(Now a postdoctoral fellow at the Research Institute of McGill University Health Centre)

Philippe Naquet (right)

Professor in Immunology at Aix Marseille University, PI at Centre d'Immunologie de Marseille-Luminy
naquet@ciml.univ-mrs.fr

Scan to read the full article ►



THE THIOL-REACTIVE COMPOUND APR-246 ENHANCES TUMOR IMMUNOGENICITY

We previously reported that activation of p53 by APR-246 reprograms tumor-associated macrophages to overcome immune checkpoint blockade resistance. Here, we demonstrate that APR-246 and its active moiety, methylene quinuclidinone (MQ) can enhance the immunogenicity of tumor cells directly.

MQ treatment of murine B16F10 melanoma cells promoted activation of melanoma-specific CD8⁺ T cells and increased the efficacy of a tumor cell vaccine using MQ-treated cells even when the B16F10 cells lacked p53. We then designed a novel combination

of APR-246 with the TLR-4 agonist, monophosphoryl lipid A, and a CD40 agonist to further enhance these immunogenic effects and demonstrated a significant antitumor response.

We propose that the immunogenic effect of MQ can be linked to its thiol-reactive alkylating ability, as we observed similar immunogenic effects with the broad-spectrum cysteine-reactive compound, iodoacetamide. Our results thus indicate that combination of APR-246 with immunomodulatory agents may elicit effective antitumor immune response irrespective of the tumor's p53 mutation status.

RESEARCHER DETAILS



Judith Michels
Postdoctoral researcher
Weill Cornell Medicine
(Now a Medical Oncologist at Institut de Cancérologie Gustave Roussy)
Image © Christine Ledroit Perrin



Divya Venkatesh
Research Associate
Weill Cornell Medicine



Jedd D. Wolchok
Meyer Director of the Sandra and Edward Meyer Cancer Center,
Weill Cornell Medicine
jwolchok@med.cornell.edu



Taha Merghoub
Deputy Director of the Sandra and Edward Meyer Cancer Center,
Weill Cornell Medicine
tmerghoub@med.cornell.edu

Scan to read the full article ►



ORIGINAL PAPER

Michels, J., D. Venkatesh, C. Liu, S. Budhu, H. Zhong, M.M. George, D. Thach, Z.-K. Yao, O. Ouerfelli, H. Liu, B.R. Stockwell, L.F. Campesato, D. Zamarin, R. Zappasodi, J.D. Wolchok, and T. Merghoub. 2023. APR-246 increases tumor antigenicity independent of p53. *Life Science Alliance*. 7 (1): e202301999.
<https://doi.org/10.26508/lsa.202301999>

Read the full collection online:

CANCER BIOLOGY 2024



Life Science Alliance (LSA) is a global, open-access, editorially independent, and peer-reviewed journal launched in 2018 by an alliance of EMBO Press, Rockefeller University Press, and Cold Spring Harbor Laboratory Press. *Life Science Alliance* is committed to rapid, fair, and transparent publication of valuable research from across all areas in the life sciences.

CONNECT WITH LSA



@LSAJournal



contact@life-science-alliance.org



Life Science Alliance

Image: © 2023 Hofstetter et al.

life-science-alliance.org



Your Trusted Supplier of Antibodies
for *in vitro* and *in vivo* Pre-Clinical
Research Since 1997

Backed by Over 20,000 Publications

ASK
ME



www.bioxcell.com

VISIT US AT AACR24
BOOTH #515

SPIN TO WIN

